Advanced search
Publication Cover
ClinicoEconomics and Outcomes Research Volume 11, 2019 - Issue
Submit an article Journal homepage
117
Views
7
CrossRef citations to date
0
Altmetric
Original Research

Overall survival of glasdegib in combination with low-dose cytarabine, azacitidine, and decitabine among adult patients with previously untreated AML: comparative effectiveness using simulated treatment comparisons

Gabriel Tremblay1 Purple Squirrel Economics, New York, NY, USACorrespondence[email protected]
,
Tracy Westley1 Purple Squirrel Economics, New York, NY, USA
,
Joseph C Cappelleri2 Pfizer Inc, New York, NY, USA
,
Bhakti Arondekar2 Pfizer Inc, New York, NY, USA
,
Geoffrey Chan2 Pfizer Inc, New York, NY, USA
,
Timothy J Bell2 Pfizer Inc, New York, NY, USA
&
Andrew Briggs3 William R Lindsay Chair of Health Economics, Health Economics and Technology Assessment, Institute of Health & Wellbeing, University of Glasgow, Glasgow, UK
 show all
Pages 551-565 | Published online: 06 Sep 2019

References

  • Deschler B, Lubbert M. Acute myeloid leukemia: epidemiology and etiology. Cancer. 2006;107(9):2099–2107. doi:10.1002/cncr.2223317019734
  • Ossenkoppele G, Lowenberg B. How I treat the older patient with acute myeloid leukemia. Blood. 2015;125(5):767–774. doi:10.1182/blood-2014-08-55149925515963
  • NCCN (National Comprehensive Cancer Network) Clinical Practice Guidelines in Oncology (NCCN Guidelines): Acute Myeloid Leukemia. Version 2 [Online]. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed  October, 2018.
  • Walter RB, Estey EH. Management of older or unfit patients with acute myeloid leukemia. Leukemia. 2015;29(4):770–775. doi:10.1038/leu.2014.21625005246
  • Dombret H, Seymour JF, Butrym A, et al. International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts. Blood. 2015;126(3):291–299. doi:10.1182/blood-2015-01-62166425987659
  • Kantarjian HM, Thomas XG, Dmoszynska A, et al. Multicenter, randomized, open-label, phase III trial of decitabine versus patient choice, with physician advice, of either supportive care or low-dose cytarabine for the treatment of older patients with newly diagnosed acute myeloid leukemia. J Clin Oncol. 2012;30(21):2670–2677. doi:10.1200/JCO.2011.38.942922689805
  • DAURISMO™ (glasdegib) tablets, for oral use. Full Prescribing Information. U.S. Food and Drug Administration. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210656s000lbl.pdf. Accessed  October, 2018.
  • Cortes JE, Heidel FH, Heuser M, et al. A Phase 2 randomized study of low dose Ara-C with or without glasdegib (PF-04449913) in untreated patients with acute myeloid leukemia or high-risk myelodysplastic syndrome. Blood. 2016;128(22):99.
  • Cortes JE, Douglas Smith B, Wang ES, et al. Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high-risk MDS: Phase 2 study results. Am J Hematol. 2018;93(11):1301–1310. doi:10.1002/ajh.2523830074259
  • Bucher HC, Guyatt GH, Griffith LE, Walter SD. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. J Clin Epidemiol. 1997;50(6):683–691.9250266
  • Phillippo DM, Ades AE, Dias S, et al. NICE DSU Technical Support Document 18: Methods for Population-adjusted Indirect Comparisons in Submissions to NICE. National Institute for Health and Care Excellence (NICE). Available from: http://nicedsu.org.uk/wp-content/uploads/2018/08/Population-adjustment-TSD-FINAL-ref-rerun.pdf. Accessed August 19, 2019.
  • Caro JJ, Ishak KJ. No head-to-head trial? Simulate the missing arms. PharmacoEconomics. 2010;28(10):957–967. doi:10.2165/11537420-000000000-0000020831304
  • Spriggs D, Griffin J, Wisch J, Kufe D. Clinical pharmacology of low-dose cytosine arabinoside. Blood. 1985;65(5):1087–1089.3995167
  • Tremblay G, Haines P, Briggs A. A criterion-based approach for the systematic and transparent extrapolation of clinical trial survival data. JHEOR. 2015;2(2):147–160.
  • Collett D. Modelling Survival Data in Medical Research. 3rd ed. Boca Raton (FL): Chapman & Hall/CRC Press; 2015.
  • Kleinbaum DG, Klein M. Survival Analysis: A Self-Learning Text. New York (NY): Springer-Verlag; 2005.
  • Schoenfeld D. Chi-squared goodness-of-fit tests for the proportional hazards regression model. Biometrika. 1980;67(1):145–153. doi:10.1093/biomet/67.1.145
  • Signorovitch JE, Sikirica V, Erder MH, et al. Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research. Value Health. 2012;15(6):940–947. doi:10.1016/j.jval.2012.05.00422999145

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.